Table 3.
The modified Rankin Scale of patients with HIBI treated with MLC901 (n = 15) versus placebo (n = 16).
| mRS | Mean (SD) | No Symptoms | No significant disability | Slight disability | Moderate disability | Moderately severe disability | Severe disability | Dead | P value* | |
|---|---|---|---|---|---|---|---|---|---|---|
| Baseline | MLC901 | 4.19 (0.65) |
0 | 0 | 0 | 2 (12.5%) | 9 (56.25%) | 5 (31.25%) | 0 | .96 |
| Placebo | 4.2 (0.77) |
0 | 0 | 1 (6.66%) | 0 | 9 (60%) | 5 (33.34%) | 0 | ||
| First month | MLC901 | 2.88 (0.61) | 0 | 0 | 4 (25%) | 10 (62.5%) | 2 (12.5%) | 0 | 0 | .21 |
| Placebo | 3.2 (0.77) | 0 | 0 | 3 (20%) | 6 (40%) | 6 (40%) | 0 | 0 | ||
| Third month | MLC901 | 2.06 (0.68) | 0 | 3 (18.75%) | 9 (56.25%) | 4 (25%) | 0 | 0 | 0 | .004 |
| Placebo | 2.87 (0.74) | 0 | 0 | 5 (33.34%) | 7 (46.66%) | 3 (20%) | 0 | 0 | ||
| Sixth month | MLC901 | 1.88 (0.61) | 0 | 4 (25%) | 10 (62.5%) | 2 (12.5%) | 0 | 0 | 0 | .001 |
| Placebo | 2.67 (0.61) | 0 | 0 | 6 (40%) | 8 (53.34%) | 1 (6.66%) | 0 | 0 | ||
HIBI = hypoxic-ischemic brain injury, mRS = modified Rankin Scale.
*
Independent t test.